Proposing a tandem AND-gate CAR T cell targeting glioblastoma multiforme

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• CAR T-cell therapy shows promise for hematological cancers but faces challenges like recurrence and toxicity.
• Glioblastoma multiforme (GBM) remains a difficult-to-treat brain tumor with limited therapeutic options.

Purpose of the Study:

• To develop a more specific and less toxic CAR T-cell therapy for glioblastoma multiforme.
• To engineer CAR T-cells that target glioblastoma stem cells with enhanced precision.

Main Methods:

• Utilized a synNotch receptor pathway linked to a tandem CAR T-cell construct.
• Engineered CAR T-cells with a single chain fragment variable targeting EGFRvIII (scfv-EGFRvIII).
• Created an AND-gate CAR T-cell requiring dual activation signals for glioblastoma stem cell targeting.

Main Results:

• The proposed CAR T-cell design functions as an AND-gate, requiring sequential activation via synNotch receptor binding to EGFRvIII and tandem CAR binding to IL-13Rα2 or CD133.
• SynNotch receptor activation, coupled with a 4-1BB costimulatory domain, drives CAR T-cell expression under the TRE promoter.
• This leads to tri-specific recognition and effective elimination of glioblastoma stem cells.

Conclusions:

• The developed synNotch-tandem CAR T-cell strategy offers a promising approach to improve glioblastoma multiforme treatment.
• This novel design enhances tumor specificity and aims to mitigate in vivo toxicities associated with CAR T-cell therapy.